Status:
UNKNOWN
Systemic Lupus Erythematosus
Lead Sponsor:
Biruni University
Conditions:
System; Lupus Erythematosus
Cognition Disorder
Eligibility:
All Genders
6-16 years
Phase:
NA
Brief Summary
Systemic lupus erythematosus (SLE) is a chronic autoimmune and inflammatory disease. The pathogenesis of SLE results from interactions between genes, hormones, and the environment; however, the exact ...
Eligibility Criteria
Inclusion
- Patients aged 6-16 years diagnosed with jSLE by a pediatric rheumatologist
- Those who have had the disease for at least one year
- Those whose medical treatments are in a stable period
- Patients willing to be rehabilitated and able to adapt to the study
Exclusion
- Cases older than 16 years old diagnosed with jSLE
- Patients with initiation of multi-organ failure
- Those whose medical treatments are in flux
- Wanting to leave the study
- Not participating in assessments
- Not attending treatment programs regularly
- Not being able to adapt to treatment programs at the cognitive level
Key Trial Info
Start Date :
August 2 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 5 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05984316
Start Date
August 2 2023
End Date
December 5 2023
Last Update
October 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Biruni University
Istanbul, Turkey (Türkiye)